AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
EVOGENE LTD.
XNAS · usd
SIC 8731 · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
FIGI BBG001SR80P1
0.36▼ 0.01 (-3.14%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
0.38
Day's Range
0.36 – 0.37
52-Week Range
0.35 – 1.33
Volume
9,099
Avg Volume
1.3M
Share Statistics
Shares Outstanding
Employees
52
Exchange
XNAS
Listed
2008-03-05
Share count as of December 31, 2025

EVOGENE LTD. (EVGN) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about EVOGENE LTD. (EVGN)
What is EVOGENE LTD.'s Market Cap?
EVOGENE LTD.'s Market Cap is $3.2M, based on as-reported figures from SEC (XBRL) filings.
What is EVOGENE LTD.'s Enterprise Value?
EVOGENE LTD.'s Enterprise Value is -$6.1M, based on as-reported figures from SEC (XBRL) filings.
What is EVOGENE LTD.'s Price / Sales?
EVOGENE LTD.'s Price / Sales is 1.9×, based on as-reported figures from SEC (XBRL) filings.
What is EVOGENE LTD.'s EV / Revenue?
EVOGENE LTD.'s EV / Revenue is n/m, based on as-reported figures from SEC (XBRL) filings.
What is EVOGENE LTD.'s EV / EBITDA?
EVOGENE LTD.'s EV / EBITDA is 0.4×, based on as-reported figures from SEC (XBRL) filings.
What is EVOGENE LTD.'s Revenue (TTM)?
EVOGENE LTD.'s Revenue (TTM) is $1.7M, based on as-reported figures from SEC (XBRL) filings.
What is EVOGENE LTD.'s Net Income (TTM)?
EVOGENE LTD.'s Net Income (TTM) is -$7.8M, based on as-reported figures from SEC (XBRL) filings.
What is EVOGENE LTD.'s EBITDA?
EVOGENE LTD.'s EBITDA is -$14.0M, based on as-reported figures from SEC (XBRL) filings.
What is EVOGENE LTD.'s Diluted EPS (TTM)?
EVOGENE LTD.'s Diluted EPS (TTM) is -0.90, based on as-reported figures from SEC (XBRL) filings.
What is EVOGENE LTD.'s EBITDA Margin?
EVOGENE LTD.'s EBITDA Margin is -847.7%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · EVGNAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017
Profit or loss [abstract]
Revenues
Cost of revenues
Gross profit
Operating expenses (income):
Research and Development Expense
Sales and marketing
Selling, General and Administrative Expense
Other expenses (income)
Total operating expenses, net
Operating loss
Financing income
Financing expenses
Financing income (loss), net
Loss before taxes on income
Taxes on income
Loss from discontinued operations, net
Loss
Attributable to:
Equity holders of the Company
Non-controlling interests
Loss—
Basic loss per share from continuing operations, attributable to equity holders of the Company
Diluted loss per share from continuing operations, attributable to equity holders of the Company
Basic loss per share from discontinued operations, attributable to equity holders of the Company
Diluted loss per share from discontinued operations, attributable to equity holders of the Company
Basic loss per share, attributable to equity holders of the Company
Diluted loss per share, attributable to equity holders of the Company